Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli
Franco
F
Galimberti
Gabriella
G
Pastore
Matteo
M
Davalli
Alberto M
AM
Bosi
Emanuele
E
D000740:Anemia / Q000139:chemically induced; D001549:Benzamides; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D007004:Hypoglycemic Agents; D007328:Insulin; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate